clinical trial Sep 20, 2022 Verismo Therapeutics to Begin Phase I Trial of Autologous Cell Therapy SynKIR-110 Sep 15, 2022 BriaCell, Caris Life Sciences Partner to Bolster New Immunotherapy Development Sep 13, 2022 Cardiff Oncology Launches Phase II Trial of PLK1 Inhibitor in RAS-Mutated Colon Cancer Sep 13, 2022 Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response Sep 13, 2022 Nearly all dMMR Colon Cancer Patients Respond in Trial of Neoadjuvant Opdivo-Yervoy Premium Sep 11, 2022 Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients Premium Sep 11, 2022 TIL Therapy Bests Yervoy in Head-to-Head Melanoma Trial; Will It Reach Patients Without Pharma? Premium Sep 10, 2022 BMS Combo Drug Opdualag Effective in Neoadjuvant NSCLC, But Maybe No Better Than Opdivo Alone Premium Sep 7, 2022 Isofol Medical Halts Colon Cancer Study After Negative Readout; Continues Subgroup Analyses Sep 1, 2022 Aston Sci. to Launch Phase II US Study of Experimental Vaccine in HER2-Low Breast Cancer Patients Aug 31, 2022 Amgen's Lumakras Bests Chemo, Meets Primary Endpoint in CodeBreak 200 Trial Aug 29, 2022 RedCloud Begins Phase I/IIa Trial in EGFR TKI-Resistant Lung Cancer Aug 25, 2022 Byondis Begins Phase I Trial of BYON3521 in Solid Tumors Aug 23, 2022 K36 Therapeutics Gets FDA Clearance to Start Phase I Trial of Multiple Myeloma Candidate Aug 22, 2022 IDRx Launches With Back-to-the-Future Combination Drug Development Strategy Premium Aug 22, 2022 Kronos Begins Trial of Second SYK Inhibitor in FLT3-Mutated AML Aug 19, 2022 Sirnaomics Launches Phase I/II Trial of RNAi Therapeutic for Facial Skin Cancer Lesions Aug 18, 2022 Innovative Cellular Therapies Begins Trial of Autologous CAR T-Cell Therapy in Colorectal Cancer Aug 17, 2022 Tessa Therapeutics Starts Trial of CAR T-Cell Therapy, BMS's Opdivo in Classical Hodgkin Lymphoma Aug 11, 2022 New Drugs Going After 'Achilles' Heel' Resistance Mutation in NSCLC Premium Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
